You can buy Lucidap at the lowest price in the online pharmacy Nextgen.ooo . Daprodustat is a low molecular weight hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor used to treat anemia in patients with chronic kidney disease. Daprodustat is a low molecular weight hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor developed by GSK. Patients with CKD are unable to induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2, and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and induces erythropoiesis.
 
In a Phase 3 clinical trial (NCT02879305), daprodustat was found to be non-inferior to erythropoiesis-stimulating agents in patients with CKD on dialysis for change from baseline in hemoglobin and cardiovascular outcomes. In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. In October 2022, the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) reaffirmed that the benefits of treatment with daprodustat outweigh the risks in adult patients with CKD anemia on dialysis, but not in patients with CKD anemia not on dialysis. On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia of chronic kidney disease in patients on dialysis.